Jubilant Ingrevia reports improved operating profit and highest PAT in five quarters

Jubilant Ingrevia, a midcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company has reported a flat performance for the quarter, with a score of 5, which is an improvement from the previous quarter's score of -12.

One of the key highlights of the financial results is the company's operating profit (PBDIT) for the quarter, which stands at Rs 124.54 crore, the highest in the last five quarters. This shows a positive trend in the company's near-term operating profit. Additionally, the operating profit margin for the quarter is also at its highest in the last five quarters, at 11.91%, indicating an improvement in the company's efficiency.

Another positive aspect of the financial results is the profit before tax (PBT) less other income, which has grown by 29.2% compared to the average PBT of the previous four quarters. The profit after tax (PAT) for the quarter is also at its highest in the last five quarters, showing a positive trend in the company's near-term profitability. The PAT has also grown by 35.6% compared to the average PAT of the previous four quarters.

The company's earnings per share (EPS) for the quarter is also at its highest in the last five quarters, at Rs 3.73. This indicates an increase in profitability and the company's ability to generate higher earnings for its shareholders.

However, there are some areas that need improvement for Jubilant Ingrevia. The company's operating cash flow for the year is at its lowest in the last three years, which could be a cause for concern. Additionally, the non-operating income for the quarter is at its highest in the last five quarters, which may not be sustainable in the long run.

Overall, Jubilant Ingrevia's financial results for the quarter ending September 2024 show a mixed performance, with some positive and negative aspects. MarketsMOJO has given a 'Hold' call for the company's stock, indicating a neutral stance. Investors may want to keep an eye on the company's future financial results to make informed decisions.